Oncopeptides AB: Interim Report Q2 2020

Oncopeptides AB: Interim Report Q2 2020

PR Newswire

STOCKHOLM, Aug. 26, 2020

STOCKHOLM, Aug. 26, 2020 /PRNewswire/ --


Financial overview April 1 - June 30, 2020      

Significant events during the period April 1 - June 30, 2020

Significant events after the reporting period

Financial overview of the group


SEK thousand

Apr - Jun

Apr - Jun

Jan - Jun

Jan - Jun

Jan - Dec

Net sales






Operating loss






Loss before tax






Loss for the period






Earnings per share before and after dilution (SEK)






Cash flow from operating activities






Cash and cash equivalents at the end of the period






Research & development costs/operating expenses %






Conference call for investors, analysts and the media
The Interim Report Q2 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides management team, Wednesday August 26, 2020 at 14:00 (CET). The conference call will also be streamed via a link on the website: www. oncopeptides.com.

Phone numbers for participants from:
Sweden: +46-8-566-427-06
Europe: +44-3333-009-274
USA: +1-833-249-84-07

Financial calendar
Interim Report Q3, 2020: November 19, 2020
Year-end Report 2020: February 18, 2021
Interim Report Q1 2021: May 26, 2021
Annual General Meeting 2021: May 26, 2021

For further information
Marty J Duvall
Oncopeptides AB
E-mail: marty.duvall@oncopeptides.com

Rein Piir
Head of Investor Relations
Oncopeptides AB
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on August 26, 2020.

About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen (melphalan flufenamide) is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Based on the results from the HORIZON study Oncopeptides has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. Oncopeptides' headquarters is in Stockholm, Sweden with its U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

For more information please visit www.oncopeptides.com.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


The full report (PDF)


Press release (PDF)


Voltar noticias em Inglês